Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kaletra/Hydroxychloroquine versus atazanavir/ritonavir/dolutegravir/hydroxychloroquine for hospitalized COVID-19
IRCT20210214050350N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Feb 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of lopinavir, ritonavir, hydroxychloroquine, atazanavir and dolutegravir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Death, ICU admission and 1 more. Started Feb 2021; status: completed.
02
Drugs
lopinavirritonavirhydroxychloroquineatazanavirdolutegravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20210214050350N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210214050350N1.